What is Global Blood Therapeutics Selling, General, & Admin. Expense?
Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Global Blood Therapeutics's selling, general, & admin. expense for the
three
months ended in Jun. 2022 was $81.1 Mil.
Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Jun. 2022 was $302.6 Mil.
Global Blood Therapeutics Selling, General, & Admin. Expense Historical Data
The historical data trend for Global Blood Therapeutics's Selling, General, & Admin. Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Global Blood Therapeutics Selling, General, & Admin. Expense Chart
Competitive Comparison of Global Blood Therapeutics's Selling, General, & Admin. Expense
For the Biotechnology subindustry, Global Blood Therapeutics's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Global Blood Therapeutics's Selling, General, & Admin. Expense Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Global Blood Therapeutics's Selling, General, & Admin. Expense distribution charts can be found below:
* The bar in red indicates where Global Blood Therapeutics's Selling, General, & Admin. Expense falls into.
Global Blood Therapeutics Selling, General, & Admin. Expense Calculation
Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.
Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $302.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Global Blood Therapeutics (NAS:GBT) Selling, General, & Admin. Expense Explanation
An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.
Warren Buffett likes companies with consistent SGA as the percentage of gross profit.
Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.
If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.
Global Blood Therapeutics Selling, General, & Admin. Expense Related Terms
Thank you for viewing the detailed overview of Global Blood Therapeutics's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.
Global Blood Therapeutics (Global Blood Therapeutics) Business Description
Global Blood Therapeutics Inc operates in the healthcare sector of the United States. It discovers and develops novel therapeutics to address blood-based disorders. GBT440, its lead drug candidate targets the underlying mechanism of red blood cell (RBC) sickling, which provides the potential to treat sickle cell disease. GBT440. an oral, once-daily therapy arrests abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. In addition, the company is engaged in other research and development activities targeted at hereditary angioedema and owns exclusively licensed rights to its portfolio of product candidates in the United States, Europe, and other major markets.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GBT has been successfully added to your 